The renal protect function of erythropoietin after release of bilateral ureteral obstruction in a rat model

Clin Sci (Lond). 2018 Sep 22;132(18):2071-2085. doi: 10.1042/CS20180178. Print 2018 Sep 28.

Abstract

Congenital urinary tract obstruction is one of the most frequent malformations in fetuses or neonates, which usually causes profound impairment of renal function including reductions in both glomerular filtration rate (GFR) and tubular handling of water and solutes. Although obstruction can be released by surgical operation, the child will suffer from diuresis for sometime. It has been reported that erythropoietin (EPO) could prevent the down-regulation of aquaporin-2 (AQP2) and urinary-concentrating defects induced by renal ischemia/reperfusion (I/R) injury. However, whether EPO could promote the recovery of renal function and AQP2 expression after releasing of ureteral obstruction has not been reported yet. The purposes of the present study were to investigate the effects of EPO on renal function and AQP2 expression after release of bilateral ureteral obstruction (BUO-R) in rats. The results showed that EPO could promote interleukin (IL) 10 (IL-10) expression; inhibit tumor necrosis factor-α (TNF-α), IL-6, and inducible nitric oxide synthase (iNOS) expressions; reduce the fractional excretion of sodium (FENa) and plasma creatinine (CREA) and urea; and promote the recovery of water and salt handling and AQP2 expression in BUO-R rats, especially in the high dose of EPO-treated group rats. In conclusion, EPO could promote the recovery of renal function and AQP2 expression in BUO-R rats, which may partially associate with its anti-inflammation effect.

Keywords: Inflammatory factors; Ureteral obstruction; aquaporin-2; erythropoietin; interleukin-10; renal function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aquaporin 2 / genetics
  • Aquaporin 2 / metabolism
  • Disease Models, Animal*
  • Erythropoietin / pharmacology*
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / physiopathology
  • Male
  • Protective Agents / pharmacology
  • Rats, Sprague-Dawley
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / physiopathology
  • Ureteral Obstruction / genetics
  • Ureteral Obstruction / metabolism
  • Ureteral Obstruction / physiopathology*

Substances

  • Aquaporin 2
  • EPO protein, human
  • Protective Agents
  • Erythropoietin